Scientists seek to better protect the eye from glaucoma

May 29, 2018, Medical College of Georgia at Augusta University
Under the increased pressure of glaucoma, scientists want to help the neurons in our eyes better protect themselves and get better help from their friends.Pictured is Medical College of Georgia ophthalmologist Dr. Kathryn Bollinger. Credit: Augusta University Senior Photographer Phil Jones

Under the increased pressure of glaucoma, scientists want to help the neurons in our eyes better protect themselves and get better help from their friends.

They are working to see whether agents that activate the innate neuron protector sigma 1 receptor, or S1R, can do both.

Current glaucoma therapies work to reduce pressure in the eye by increasing outflow and/or reducing fluid production.

Dr. Kathryn Bollinger, ophthalmologist, glaucoma specialist and retinal cell biologist, has evidence that a good additional strategy would be directly enhancing protection of neurons in our eyes, called retinal ganglion cells, hopefully by directly activating S1R.

"We may be able to protect the retinal ganglion cells more long term," says Bollinger, a faculty member in the Department of Ophthalmology at the Medical College of Georgia and James and Jean Culver Vision Discovery Institute at Augusta University and recent recipient of a $1.5 million grant from the National Eye Institute.

S1R stimulation has been shown to protect retinal ganglion cells in other disease models, but hers appears to be the first work in glaucoma, Bollinger says of the protein that is expressed in both neurons and their astrocytes throughout our visual system. Her work over the past year, funded by a mid-career physician scientist grant from the American Glaucoma Society, has focused on the impact of activating S1R in the astrocytes.

The new grant is enabling her to also look at whether activating S1R, with existing drugs already used in patients for other reasons, also enables neurons to better protect themselves.

The high pressure glaucoma produces inside the eye seems to transform astrocytes, a type of brain cell that provides nutrition and other support to the neurons, into a nemesis that instead releases toxically high levels of things like nitric oxide and reactive oxygen species.

In a rat model of glaucoma, Bollinger's team is further exploring the impact of activating S1R with known agonists like the pain reliever pentazocine and commonly used antidepressants called selective serotonin reuptake inhibitors. They are looking at their impact on neuron survival and function and the level of support from protective proteins like brain-derived neurotrophic factor, which aids neuron survival as well as new neuron growth.

One question Bollinger and her team want to answer is how/if these drugs can protect and/or rescue neurons in the face of glaucoma.

They are looking again, in culture and their animal model, at what they suspect is S1R's role in mediating the reactivity of astrocytes. Astrocytes' increased reactivity, in turn, appears to prompt release of neurotoxic substances like the high levels of nitric oxide, which further raises pressure and reactivity.

But when scientists treat the usually supportive cells with S1R agonists in a dish, the cells back off their bad behavior and appear more willing to release good things like brain-derived neurotrophic factor. Bollinger notes that some astrocyte changes in response to pressure may actually be helpful to neurons while others are deleterious, which is something else she wants to understand.

"As we kind of piece together the specific consequences of astrocyte activation, we might be able to better manipulate astrocytes so they will again just protect neurons instead of damage neurons," Bollinger says. "That is our hope."

Her team already has good evidence that changes in astrocyte behavior occur rather quickly in response to increased pressure in the tight confines of the eyeball.

Now they also are looking at whether activating S1R increases the neurons' own response to negatives like oxidative stress.

"We still don't have those answers," Bollinger says. But they have seen neurons in a dish without their astrocytes garner stress protection from S1R agonists.

"We know that S1R agonists protect in culture. If we can understand exactly how this occurs then potentially we could come up with a more effective target for treatment," Bollinger says.

While she hopes activating S1R works both ways to protect neurons, the bottom line that matters is that it works, Bollinger says.

Bollinger's team has no evidence that SIR activity is decreased by glaucoma, rather she suspects the need for SIR increases with this condition.

While patients with glaucoma may experience some level of decreased vision, a minority will experience blindness, and there is no way to predict who those patients are and no additional means to intervene.

"Given our aging population and the fact that glaucoma is prevalent, we do see blindness secondary to glaucoma," Bollinger says. Conversely, some patients may never experience any vision loss.

For the studies, the S1R agonists are injected into the abdominal cavity, but a topical application could be developed if the findings continue to hold, she adds.

Glaucoma is the second leading cause of blindness, and lost vision cannot currently be regained, according to the Glaucoma Research Foundation. Although it tends to occur in older individuals, some babies are born with glaucoma and young adults, particularly African-Americans, can have it as well.

In glaucoma, the pressure likely builds from unhealthy changes in the drainage tracts in the front of the eye that can come with aging, like reduced flexibility and increased scarring of that delicate tissue.

Lab animals with S1R deleted have slowly progressing, age- associated death of neurons in the eye similar to what happens in .

Their efforts to rejuvenate and regenerate neurons in the eye are likely relevant as well to in the brain and peripheral nervous system, Bollinger says. For example, S1R recently has been shown to have a role in amyotrophic lateral sclerosis, ALS or Lou Gehrig's disease, which affects the nerve cells that control muscles. S1R agonists have been shown to be beneficial as well in animal models of this condition, she says.

Explore further: Pain reliever may help relieve the vision damage of glaucoma

Related Stories

Pain reliever may help relieve the vision damage of glaucoma

May 1, 2017
The tip of our optic nerve is typically the first place injured by glaucoma.

Keto diet protects optic nerve in glaucoma mouse model

May 14, 2018
Switching mice destined to develop glaucoma to a low carbohydrate, high fat diet protects the cells of the retina and their connections to the brain from degeneration, according to research published in JNeurosci. The study ...

Glaucoma's unique protein expression could enhance diagnosis and treatment

May 4, 2010
An eye under pressure appears to express a unique set of proteins that physicians hope will one day help them better diagnose and treat glaucoma.

Early retina cell changes in glaucoma identified

February 11, 2015
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular ...

Aqueous humor, microRNAs and glaucoma

April 11, 2018
Glaucoma—the leading cause of vision loss worldwide—includes a heterogeneous group of disorders. Primary open-angle glaucoma (POAG) and exfoliation glaucoma (XFG) are linked to decreased outflow of aqueous humor, which ...

Research advance may lead to new treatments for glaucoma

March 22, 2016
Researchers have developed a tool to not only model the underlying disease mechanisms of glaucoma, but also to help discover and test new pharmacological strategies to combat the neurodegeneration that occurs in patients ...

Recommended for you

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.

Gene therapy breakthrough in treating rare form of blindness

October 9, 2018
Positive results of the world's first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in Nature Medicine.

Gene changes driving myopia reveal new focus for drug development

October 9, 2018
Myopia (nearsightedness) and hyperopia (farsightedness) develop through different molecular pathways, according to a new study publishing October 9 in the open-access journal PLOS Biology by Andrei Tkatchenko of Columbia ...

Dynamin-binding protein linked to congenital cataracts

October 4, 2018
Cataracts, a condition in which the eyes' natural lenses get clouded, are the most common cause of vision loss in older people and can be corrected by routine surgery. But congenital cataracts, which occur in infants and ...

Eye discovery to pave way for more successful corneal transplants

October 1, 2018
A team of eye specialists at The University of Nottingham has made another novel discovery that could help to improve the success of corneal transplants for patients whose sight has been affected by disease.

New study confirms Mediterranean diet prevents a leading cause of blindness

October 1, 2018
Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD), a leading cause of blindness in the United States. A large collaboration of researchers from the ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

shortwave02001
not rated yet Jul 20, 2018
I am from Jamaica and our scientists developed a drug from marijuana and was delivered to the eyes in the firm of drops.This drug reduced the eyes intra-occular pressure and was available in Jamaica and the Caribbean over the last 30 years.One of the developers of that drug has made a
major innovation as the drug can now be administered sublingually, The first name of the eye drops was Canasol. the new drug goes on sale in Jamaica this month and is more effective with less cannaboloid. The researcher is Dr. Henry Lowe and his work can be googled.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.